Xvivo Perfusion AB
STO:XVIVO

Watchlist Manager
Xvivo Perfusion AB Logo
Xvivo Perfusion AB
STO:XVIVO
Watchlist
Price: 186.4 SEK -0.75% Market Closed
Market Cap: kr5.9B

Wall Street
Price Targets

XVIVO Price Targets Summary
Xvivo Perfusion AB

Wall Street analysts forecast XVIVO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for XVIVO is 312.12 SEK with a low forecast of 247.45 SEK and a high forecast of 404.25 SEK.

Lowest
Price Target
247.45 SEK
33% Upside
Average
Price Target
312.12 SEK
67% Upside
Highest
Price Target
404.25 SEK
117% Upside
Xvivo Perfusion AB Competitors:
Price Targets
LFMD
LifeMD Inc
130% Upside
ARGX
argenx SE
47% Upside

Revenue
Forecast

23% / Year
Past Growth
27% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
23% / Year
Past Growth
27% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

For the last 12 years the compound annual growth rate for Xvivo Perfusion AB's revenue is 23%. The projected CAGR for the next 3 years is 27%.

Operating Income
Forecast

19% / Year
Past Growth
66% / Year
Estimated Growth
Estimates Accuracy
-16%
Average Miss
19% / Year
Past Growth
66% / Year
Estimated Growth
Estimates Accuracy
-16%
Average Miss

For the last 12 years the compound annual growth rate for Xvivo Perfusion AB's operating income is 19%. The projected CAGR for the next 3 years is 66%.

Net Income
Forecast

10% / Year
Past Growth
130% / Year
Estimated Growth
Estimates Accuracy
-45%
Average Miss
10% / Year
Past Growth
130% / Year
Estimated Growth
Estimates Accuracy
-45%
Average Miss

For the last 12 years the compound annual growth rate for Xvivo Perfusion AB's net income is 10%. The projected CAGR for the next 3 years is 130%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is XVIVO's stock price target?
Price Target
312.12 SEK

According to Wall Street analysts, the average 1-year price target for XVIVO is 312.12 SEK with a low forecast of 247.45 SEK and a high forecast of 404.25 SEK.

What is Xvivo Perfusion AB's Revenue forecast?
Projected CAGR
27%

For the last 12 years the compound annual growth rate for Xvivo Perfusion AB's revenue is 23%. The projected CAGR for the next 3 years is 27%.

What is Xvivo Perfusion AB's Operating Income forecast?
Projected CAGR
66%

For the last 12 years the compound annual growth rate for Xvivo Perfusion AB's operating income is 19%. The projected CAGR for the next 3 years is 66%.

What is Xvivo Perfusion AB's Net Income forecast?
Projected CAGR
130%

For the last 12 years the compound annual growth rate for Xvivo Perfusion AB's net income is 10%. The projected CAGR for the next 3 years is 130%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett